Solid Biosciences' Gabriel Brooks sells 4,374 shares

Q: How many SLDB shares did Chief Medical Officer Gabriel Brooks sell, and at what price?

Gabriel Brooks sold 4,374 shares at $5.62 per share on October 19, 2026, to cover withholding taxes following RSU vesting. The sale was not discretionary and followed a durable automatic sale instruction letter adopted August 15, 2024; it was reported under a Rule 10b5-1 plan.

Q: How many SLDB shares did Gabriel Brooks acquire when RSUs converted?

On October 18, 2026, Gabriel Brooks acquired 9,750 common shares when 9,750 restricted stock units converted into common stock on a one-for-one basis.

Q: What was the vesting schedule for Gabriel Brooks's SLDB RSUs?

The RSUs were granted on October 18, 2023. 25% of the original number of shares vested on each anniversary until the fourth anniversary of the grant date.

The 4,374-share sale covered withholding taxes following RSU vesting and was described as non-discretionary under an automatic sale instruction.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Solid Biosciences Inc. Chief Medical Officer Gabriel Brooks converted 9,750 restricted stock units into 9,750 common shares on October 18, 2026. On October 19, he sold 4,374 shares at $5.62 per share to cover withholding taxes following RSU vesting. The sale was not discretionary; it followed a durable automatic sale instruction letter adopted August 15, 2024, and was reported under a Rule 10b5-1 plan.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Brooks Gabriel

Role Chief Medical Officer

Sold 4,374 shs ($25K)

Approx. gross sale proceeds $25K

Type	Security	Shares	Price	Value
Sale	Common Stock ^F3	4,374	$5.62	$25K
Exercise	Restricted Stock Units ^{F1, F4}	9,750	$0.00	$0.00
Exercise	Common Stock ^{F1, F2}	9,750	--	--

Holdings After Transaction: Restricted Stock Units — 9,750 contracts (Direct); Common Stock — 97,241 shares (Direct)

Footnotes (4)

F1. Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2. Includes 2,399 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 29, 2026.
F3. This sale was made to cover withholding taxes following the vesting of previously granted RSUs pursuant to a durable automatic sale instruction letter adopted by Dr. Brooks on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Brooks.
F4. The RSUs were granted on October 18, 2023 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

Key Figures

Common shares sold: 4,374 shares Sale price: $5.62 per share Restricted stock units converted: 9,750 RSUs +3 more

6 metrics

Common shares sold 4,374 shares October 19, 2026

Sale price $5.62 per share Sale on October 19, 2026

Restricted stock units converted 9,750 RSUs October 18, 2026

Common shares acquired 9,750 shares Conversion on October 18, 2026

Annual vesting portion 25% Of the original number of shares, on each anniversary

Vesting period Four years RSUs vest on each anniversary through the fourth anniversary

Key Terms

Restricted stock units, sell-to-cover election, durable automatic sale instruction letter

3 terms

Restricted stock units financial

"Restricted stock units (“RSUs”) convert into common stock on a one-for-one basis"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

sell-to-cover election financial

"effecting the sell-to-cover election"

durable automatic sale instruction letter financial

"pursuant to a durable automatic sale instruction letter"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many SLDB shares did Chief Medical Officer Gabriel Brooks sell, and at what price?

Gabriel Brooks sold 4,374 shares at $5.62 per share on October 19, 2026, to cover withholding taxes following RSU vesting. The sale was not discretionary and followed a durable automatic sale instruction letter adopted August 15, 2024; it was reported under a Rule 10b5-1 plan.

How many SLDB shares did Gabriel Brooks acquire when RSUs converted?

On October 18, 2026, Gabriel Brooks acquired 9,750 common shares when 9,750 restricted stock units converted into common stock on a one-for-one basis.

What was the vesting schedule for Gabriel Brooks's SLDB RSUs?

The RSUs were granted on October 18, 2023. 25% of the original number of shares vested on each anniversary until the fourth anniversary of the grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/20/2026 - 04:05 PM EDT Accepted by SEC EDGAR 10/20/2026 - 04:05 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brooks Gabriel

(Last)

(First)

(Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN

MASSACHUSETTS

02129

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/18/2026		M		9,750	A	⁽¹⁾	101,615⁽²⁾	D
Common Stock	10/19/2026		S		4,374⁽³⁾	D	$5.62	97,241	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	10/18/2026		M			9,750	⁽⁴⁾	⁽⁴⁾	Common Stock	9,750	$0	9,750	D

Explanation of Responses:

1. Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

2. Includes 2,399 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 29, 2026.

3. This sale was made to cover withholding taxes following the vesting of previously granted RSUs pursuant to a durable automatic sale instruction letter adopted by Dr. Brooks on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Brooks.

4. The RSUs were granted on October 18, 2023 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

	/s/ Kimberly Cornwell as attorney-in-fact for Gabriel Brooks	10/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR